Imagine trying to send a letter through a thick layer of honey; that is how hard it is for medicine to reach lung cells because of mucus. This project creates tiny, engineered bubbles from stem cells that act like specialized delivery vehicles to slip through that honey. These bubbles carry genetic instructions and are sprayed directly into the lungs using a high-tech nebulizer.
Current RNA therapies struggle to reach lung tissues because of the thick mucus barrier and poor cell membrane penetration. This prevents effective treatment of lung cancer, a disease with poor survival rates.
A combined system consisting of bioengineered stem cell EVs (OS003) for RNA transport and a vibrating mesh nebulizer for aerosol delivery.
If you are a gene therapy developer dealing with the inability to target organs other than the liver or kidney — this project developed a bioengineered Extracellular Vesicle (EV) platform that penetrates the lung mucus barrier to deliver RNA payloads.
If you are a nebulizer manufacturer dealing with inefficient delivery of complex biologics — this project developed a vibrating mesh nebulizer technology specifically tailored for aerosol delivery of advanced therapeutics.
If you are an ATMP manufacturer dealing with the difficulty of scaling cell-derived vesicles — this project developed process development and CMC for the scalable manufacturing of OS003 EVs.
Based on available project data, specific pricing or cost structures are not provided.
Yes, the project includes a partner, EVER, specifically tasked with process development and CMC for scalable manufacturing of the OS003 EVs.
The project utilizes proprietary surface engineering technology from OMNI and proprietary vibrating mesh nebulizer technology from AERO; however, specific licensing terms are not listed.
OMNI is responsible for commercialisation and regulatory communication as part of the project's second work package.
The project is active from 2022-06-01 and is scheduled to conclude on 2026-02-28.
The consortium is heavily industry-driven with a 78% industry ratio, comprising 7 industrial partners (including 5 SMEs) and only 2 academic/research entities. This structure suggests a strong focus on commercial viability and manufacturing rather than pure academic research, with specialized roles split between device development (AERO), manufacturing (EVER), and therapeutic optimization (OMNI).
Contact Myriad Consulting Limited in Ireland for project coordination details.
Contact us to explore licensing opportunities for the OS003 EV delivery platform.
